Grabovac 2017.

Study characteristics
Methods	Study design: non‐randomised intervention study Country: Germany and Austria Data collection period: not stated Registry ID: not reported
Participants	Number of participants: N = 447; Number included in meta‐analysis: N = 224 Sample characteristics (at baseline): Age (mean): 45.5 years (range 21 ‐ 82); Sex (% male): 86.4% (386/447) Population category: chronic physical condition; Specific population: people living with HIV Nicotine dependence: not measured; Baseline cigarettes per day: up to 10 (24.0%), 11 – 20 (37.1%), 21 – 30 (22.2%), 31+ (13.1%); Motivation to quit: selected by motivation to quit
Interventions	Behavioural support for smoking cessation: 2 smoking cessation interventions delivered by trained physicians were offered to all people who smoked; a short intervention (5‐minute structured motivational intervention focused on increasing knowledge about benefits of smoking cessation) and a longer programme (full smoking cessation programme) with 5 sessions (approximately 30 minutes, focused on strengthening problem‐solving skills and developing social skills to improve patient social support) – people who smoked were invited to participate in full programme after short intervention, time‐frame between sessions was not pre‐determined to facilitate flexibility Pharmacological support for smoking cessation: pharmacological support (nicotine replacement products, bupropion, varenicline) was offered for participants to use if they wished; 4.0% participants received nicotine replacement products, 2.7% participants received varenicline and 1.8% bupropion in the recommended dosages Psychotherapeutic or psychoactive support for mental health or mood: some of the sample received mood‐management intervention (1.8% of participants; n = 4) received bupropion and 16% of total sample (14% of people who smoked) were receiving ‘antidepressant therapy’ not otherwise specified
Outcomes	Definition of cessation used: smoking status assessed with question ‘have you smoked within the last 7 days’ i.e. point‐prevalence abstinence Cessation definition used for outcome(s) in this analysis: point‐prevalence abstinence Measure of biovalidation: smoking status at baseline confirmed with CO level of > 6 ppm ; smoking status measured at study end using same protocol (i.e. CO measured at study end) but does not explicitly state it was used to confirm abstinence Definition of people who continued to smoke used: ‘participants who continued to smoke’ i.e. reported smoking in the previous 7‐days Time point(s) at which follow‐up was conducted: 8 months Outcome category: Psychological Quality of Life (QoL), Social Outcome Outcome measure(s): World Health Organisation Quality of Life – HIV‐Bref (WHOQOL HIV‐Bref)
Funding source	Study was funded by ViiV healthcare Germany and GSK Austria
Author conflicts of interest	The authors report no conflict of interest
Notes	Outcome data source: Published data